For too long Poor Case Detection has continued to remain a major health care problem, resulting in a huge burden to the patient (tremendous over treatment/under treatment) and society, (huge ...implications of cost and drug resistance). Conventional testing methodologies for a variety of infectious and communicable diseases based on so called "Gold Standard" but grossly in adequate platforms have only added to the patient's misfortune. Also the fact that to even take advantage of such existing tests a patient has to necessarily travel long distances to tertiary level centers to give his/her sample for testing and then undergo an agonizing wait for the results of the tests to be known and then for the treatment to get started. Current mdx (molecular diagnostic) platforms using the realtime PCR principles, considered most sensitive and specific, while promising greatly improved delivery of patient care through expedited diagnosis, improved treatment efficacy, have as a matter of fact neither delivered nor met the expectations of "quantum leap in laboratory testing standards". Various complexities and short comings have led to them iniscule use of such a unique technology for the betterment of global health care settings. Not anymore-Leveraging synergies of Bio Micro Electro Mechanical Systems (Bio MEMS) & Polymerase Chain Reaction(PCR), the True lab Real Time micro PCR system, brings real time PCR testing to near patient & Point Of Care (POC) settings for early diagnosis & better patient care & allows the patient-you, to rest assured.
In this paper, four established cell lines derived from newly hatched larvae of Papilio demoleus Linnaeus and 57 single-cell clones derived from the 3 lines were used as test materials. Recombinant ...β-galactosidase baculovirus AcMNPV-Gal was used to infect the P. demoleus L. cell lines and the single-cell clones, and recombinant protein expression in each cell line was detected and compared. Three clonal cell lines, RIRI-PaDe-l-Cl, RIRI-PaDe-2-C6 and RIRI-PaDe-3-C52, which showed significantly higher β-galactosidase expression levels than those of the parental cell lines, were selected. Five types of commercial serum-free media for insect cells, Express Five SFM, Ex-Cell 405, Sf-900III SFM, Sf-900II SFM and HyClone Serum-Free Media, were used to adapt RIRI-PaDe-2-C6 cells and RIRI-PaDe-3-C52 cells to serum-free culture conditions, and the growth characteristics of the cells and the exogenous protein expression characteristics before and after adaptation were compared. The results showed that RIRI-PaDe-2-C6 cells could stably proliferate in Ex-Cell 405, RIRI-PaDe-3-C52 cells could stably proliferate in Express Five SFM and Ex-Cell 405, and the rate of proliferation of and the level of expression of β-galactosidase in RIRI-PaDe-3-C52 cells were significantly increased in Express Five SFM.
Biotechnology and law are inextricable. Patent, regulatory, and contract law profoundly shape the biotech industry, and each of these practice areas is deeply intertwined with the science it governs. ...Yet many in this industry lack even a basic grasp of these laws, jeopardizing their business success as a result. This book is an essential introduction to biotechnology law for scientists, startup founders, regulatory specialists, patent liaisons, investors, academics, students, and other nonattorneys with biotech backgrounds. It covers core topics such as patentability, patent prosecution and infringement, patent opinions, the development and FDA approval of small-molecule and biologic drugs, regulatory exclusivity, generic drugs and ANDA litigation, biosimilars and the patent dance, patent licenses, and collaboration agreements. Written with scientists in mind,Biotechnology Law is a clear, concise, and entirely practical primer on the topic, replete with straightforward, real-world examples to illustrate each key concept. Understanding the legal machinery through which science becomes business is not a luxury-it is a crucial part of a scientist's training. Alan J. Morrison's expert treatment embraces this new reality.
Stroke can lead to the serious long-term neurological disability. The dysregulation of long non-coding RNAs (IncRNAs) has been proven to be a pivotal factor for the progression of ischemie stroke. ...However, it is largely unknown whether IncRNAs regulated the OGD/R injury of cerebral microglial cells. In this study, we designed experiments to reveal the role of IncRNA Nuclear Enriched Abundant Transcript 1 (NEAT1) in the OGD/R injury of microglial cells. We found that NEAT1 contributed to the OGD/R injury and neuroinflammation damage in microglial cells. Moreover, the molecular mechanism involved in the NEAT1mediated OGD/R injury. Mechanism investigation revealed that NEAT1 was upregulated by the transcription factor YY1. Moreover, Western blot analysis suggested that NEAT1 enhance the protein levels of core factors of Wnt/β-catenin signaling pathway, indicating that NEAT1 contributed to the activation of Wnt/β-catenin signaling pathway. Rescue assays were carried out in the microglial cells treated with OGD/R. The results showed that NEAT1 regulated the OGD/R injury and neuroinflammation damage via Wnt/β-catenin signaling pathway. In conclusion, our findings suggested that YY1-induced upregulation of NEAT1 contributed to the OGD/R injury and neuroinflammation damage of microglial cells via Wnt/β-catenin signaling pathway.
PDF
